VetMedGuide

Vet Med Guide

Pharmaceuticals2026-05-16 · 9 min read

Meloxicam for Dogs: NSAID Pain Relief, Safety, and What Monitoring Actually Catches

A label-first guide to meloxicam (Metacam) for dogs: how this COX-2-preferential NSAID works, which dogs benefit from it, what side effects to watch for, and why cats are different.

Ran Chen
Ran Chen
Founder, VetMedGuide. Life-sciences operator and 10× global market-access lead.
Published

Meloxicam — most commonly dispensed under the brand name Metacam — is an FDA-approved non-steroidal anti-inflammatory drug (NSAID) for dogs. It is one of the most frequently prescribed veterinary NSAIDs worldwide, used primarily for osteoarthritis pain and post-surgical inflammation.

It is also a drug where the gap between "generally safe when used correctly" and "dangerous when misused" is narrow. This article covers what the label says, how meloxicam's COX-2 preference works, what the side-effect profile looks like in practice, and the critical difference between meloxicam use in dogs and cats.

How meloxicam works

Meloxicam belongs to the oxicam class of NSAIDs. It works by inhibiting cyclooxygenase (COX) enzymes, which produce prostaglandins — the chemical messengers that drive inflammation, pain, and fever.

The body has two main COX enzymes:

  • COX-1 is constitutive. It produces prostaglandins that protect the stomach lining, support kidney blood flow, and help platelets function normally. Inhibiting COX-1 causes most of the side effects associated with NSAIDs — GI ulcers, kidney damage, and bleeding.
  • COX-2 is induced at sites of inflammation. It produces the prostaglandins that cause pain, swelling, and fever. Inhibiting COX-2 provides the therapeutic benefit of NSAIDs.

Meloxicam is COX-2 preferential. In canine whole blood assays, it is approximately 2.7 to 10 times more selective for COX-2 than COX-1, according to the Merck Veterinary Manual. This means it spares more of the protective COX-1 pathway than older non-selective NSAIDs, reducing — but not eliminating — the risk of GI and renal side effects.

Meloxicam is highly protein-bound (approximately 97%) and has a relatively long elimination half-life in dogs — greater than 12 hours. This pharmacokinetic profile supports once-daily dosing.

What the FDA label covers

In the United States, meloxicam is FDA-approved for dogs under the brand name Metacam (Boehringer Ingelheim). The labeled indications are:

  • Osteoarthritis pain and inflammation. Long-term daily use for chronic OA management.
  • Postoperative pain. Short-term use after soft tissue and orthopedic surgeries.

The injectable formulation of Metacam is also approved for a single dose in cats for postoperative pain control after spays, neuters, and orthopedic surgeries. This is the only approved feline use in the US. Oral meloxicam is not approved for cats in the United States, and repeated dosing in cats has been associated with acute renal failure and death. This distinction matters and is covered in detail below.

It is worth noting that the international landscape is different: in Europe, Canada, Australia, and New Zealand, long-term oral meloxicam at the 0.5 mg/mL feline concentration is registered, approved, and widely used for chronic pain in cats. Research supports its benefit in feline patients when appropriately dosed and monitored. This international approval does not change the US label — but it does explain why some pet owners who have lived abroad or read international veterinary sources encounter conflicting information.

Dosing

According to the Metacam label and the Merck Veterinary Manual:

  • Loading dose: 0.2 mg/kg orally on the first day
  • Maintenance dose: 0.1 mg/kg orally once daily thereafter
  • Titration: Once a therapeutic effect is achieved, the dose should be titrated to the lowest effective dose for that individual dog

Metacam is available as an oral suspension (0.5 mg/mL and 1.5 mg/mL) with a dosing syringe calibrated to the dog's weight. This liquid formulation makes it easy to adjust doses precisely and is generally well accepted by dogs when dropped onto food.

An injectable formulation (5 mg/mL) is available for subcutaneous or intravenous use in the clinic, typically given as a pre-operative or peri-operative dose.

Key dosing precautions

  • Meloxicam should be given with food to reduce the risk of GI upset.
  • If a dose is missed, it should be given as soon as remembered, but never doubled.
  • The lowest effective dose should always be the goal, particularly for long-term use.

Side effects and what to watch for

As with all veterinary NSAIDs, the primary risk categories are gastrointestinal, renal, and hepatic. The FDA CVM has published guidance emphasizing that no NSAID is considered safer than another — the response is individualized, and every NSAID can cause side effects.

Gastrointestinal effects (most common)

Vomiting, diarrhea, decreased appetite, melena (dark tarry stools), and abdominal pain. These are the effects owners are most likely to notice first. Mild GI signs that appear in the first few days may be transient, but persistent or worsening symptoms — especially dark stools or vomit that looks like coffee grounds — require stopping the drug and contacting a veterinarian immediately.

GI ulcers and perforation are rare but serious. The risk increases when meloxicam is combined with corticosteroids (such as prednisone) or other NSAIDs. This combination should be avoided.

Renal effects

Meloxicam reduces prostaglandin synthesis in the kidneys, where prostaglandins help maintain blood flow. In healthy, well-hydrated dogs, this is usually tolerated. In dehydrated dogs, dogs with pre-existing kidney disease, or dogs on concurrent diuretic therapy, the reduction in renal blood flow can lead to acute kidney injury.

Dogs starting long-term meloxicam should have baseline kidney values (BUN, creatinine, SDMA, and urinalysis) checked before the first dose and at regular intervals during treatment — typically every 6 months, or more frequently if kidney disease is present.

Hepatic effects

Elevated liver enzymes have been reported with meloxicam use, as with other NSAIDs. Idiosyncratic hepatotoxicity is unpredictable and not dose-dependent. The FDA notes that liver enzyme elevations may occur in dogs on any NSAID, and monitoring should include periodic liver panels.

When to stop the drug and call the vet

  • Vomiting blood or material that looks like coffee grounds
  • Black, tarry stools
  • Sudden increase in drinking and urination
  • Jaundice (yellowing of gums, eyes, or skin)
  • Lethargy or collapse
  • Any signs that suggest the dog is getting worse rather than better

Drug interactions and contraindications

The Metacam label lists the following contraindications:

  • Dogs with known hypersensitivity to meloxicam
  • Dogs with bleeding disorders (safety not established)
  • Concurrent use with other NSAIDs or corticosteroids

Washout periods

When switching between NSAIDs, a washout period is essential to reduce the risk of overlapping GI and renal toxicity. The dvm360 proceedings on responsible NSAID use recommend:

  • 5-day washout between most NSAIDs
  • 10-day washout specifically for aspirin and meloxicam, due to meloxicam's long half-life and aspirin's irreversible platelet effects

This means if a dog is on meloxicam and a veterinarian wants to switch to carprofen (Rimadyl) or grapiprant (Galliprant), the dog should be off meloxicam for at least 5 days — and ideally 10 — before starting the new drug. The same applies in reverse.

Other interactions

  • Diuretics (furosemide, spironolactone): increased risk of dehydration and renal toxicity. Use together only with close monitoring.
  • ACE inhibitors (benazepril, enalapril): may reduce the antihypertensive effect and increase renal risk. Monitor kidney values closely.
  • Aminoglycoside antibiotics: additive nephrotoxicity risk.

Meloxicam vs other veterinary NSAIDs

The FDA CVM explicitly states that no one NSAID is considered more effective than another — the response is individualized. The choice between meloxicam, carprofen, grapiprant, deracoxib, robenacoxib, and firocoxib depends on the individual dog's response, comorbidities, and what the veterinarian has found works best.

NSAID Brand COX selectivity Approved species Key notes
Meloxicam Metacam COX-2 preferential Dogs (oral); cats (single injection) Once-daily liquid; long half-life
Carprofen Rimadyl, generics COX-2 preferential Dogs only Most widely prescribed vet NSAID
Grapiprant Galliprant EP4 receptor antagonist Dogs only Different mechanism; may be easier on kidneys
Deracoxib Deramaxx COX-2 selective Dogs only More COX-2 selective than meloxicam
Robenacoxib Onsior COX-2 selective Dogs and cats (max 3 days) Short-acting; surgical use

The cat warning

This section exists because the difference between meloxicam use in dogs and cats is a matter of life and death, and it is not always well understood by pet owners.

In the United States, the Metacam label explicitly states: "Do not use Metacam Oral Suspension in cats. Acute renal failure and death have been associated with the use of meloxicam in cats."

The injectable formulation is approved for a single pre-operative dose in cats. That single dose is considered safe. However, repeated oral dosing in cats — which is common practice in some countries and in extra-label use — has been associated with acute kidney injury and death. Cats are more sensitive to NSAID toxicosis than dogs, and no NSAID is approved for long-term use in cats in the United States.

Dog-strength oral meloxicam should never be given to a cat. The concentration difference alone can cause a dangerous overdose.

Monitoring for dogs on long-term meloxicam

The standard monitoring schedule recommended by VIN Veterinary Partner and consistent with label guidance:

  1. Before starting: Complete physical exam, CBC, chemistry panel (including liver enzymes, BUN, creatinine), and urinalysis. This establishes baseline organ function.
  2. 2–4 weeks after starting: Recheck chemistry panel to check for early liver or kidney changes.
  3. Every 6 months ongoing: Chemistry panel and urinalysis for stable dogs on long-term therapy.
  4. Any time signs of adverse effects appear: Stop the drug and recheck immediately.

The goal of monitoring is to catch organ changes early, when stopping or reducing the drug can reverse the problem, rather than waiting until damage is irreversible.

What to ask your veterinarian

  • Is my dog's kidney and liver function normal before starting? Baseline bloodwork should be current.
  • What dose is being prescribed, and is it the lowest effective dose? The label recommends titrating to the lowest dose that controls pain.
  • How often should we recheck bloodwork? Long-term use requires periodic monitoring.
  • What other medications is my dog on? NSAID interactions with steroids, diuretics, and other NSAIDs can be dangerous.
  • What signs should I watch for at home? Knowing the early warning signs of GI, renal, and hepatic side effects allows earlier intervention.

Sources

Topics
Canine Osteoarthritis
Related Articles